Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases

Neurotoxicology and Teratology

Volumn 24, Issue 5, 2002, Pages 667-673

  Berry, M D ^a   Boulton, A A ^a  

^a ALviva Biopharmaceuticals Inc   (Canada)

Author keywords

Aliphatic propargylamine; Antiapoptotic; Neural rescue; Neurodegeneration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; ALIPHATIC AMINE; AMINOETHANEPHOSPHONIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; N METHYL BETA ALANINATE; N METHYL BETA ALANINE; N METHYLAMINOETHANEPHOSPHONIC ACID; N METHYLAMINOETHANETETRAZOLE; N METHYLAMINOPROPIONITRILE; N METHYLPROPARGYLAMINE; NEUROPROTECTIVE AGENT; NOR BETA ALANINATE; NOR BETA ALANINE; NORAMINOETHANEPHOSPHONATE; NORAMINOETHANETETRAZOLE; NORAMINOPROPIONITRILE; NORPROPARGYLAMINE; PROPARGYLAMINE; PROTEIN P53; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING SITE; BRAIN ISCHEMIA; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG METABOLISM; ENANTIOMER; FACIAL NERVE INJURY; IN VITRO STUDY; IN VIVO STUDY; MOUSE STRAIN; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PARGYLINE; PARKINSONIAN DISORDERS; PROPYLAMINES;

PRIMATES;

EID: 0036715407     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(02)00217-9     Document Type: Conference Paper

References (41)

1. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
2. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
3. Defective humoral responses and extensive intravascular apoptosis associated with fatal outcome in Ebola virus-infected patients
4. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
5. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin
6. +-induced apoptosis
7. R-2HMP: An orally active agent combining independent antiapoptotic and MAO-B-inhibitory activities
8. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis
9. Programmed cell death: Does it play a role in Parkinson's disease?
10. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum
11. Reduced apoptosis after NGF and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer
12. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
13. Metabolism and pharmacokinetics, in the rat, of (R)-N-(2-heptyl)methyl-propargylamine (R-2HMP), a new potent monoamine oxidase inhibitor and antiapoptotic agent
14. PET studies of functional compensation in a primate model of Parkinson's disease
15. P53 Involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule neurons
16. Involvement of p53 in DNA strand break-induced apoptosis in postmitotic CNS neurons
17. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
18. TUNEL-positive ganglion cells in human primary open-angle glaucoma
19. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
20. Neurodegeneration in Alzheimer disease. Is apoptosis involved?
21. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
22. Apoptosis and expression of DNA repair proteins in ischaemic brain injury in man
23. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
24. Histochemical detection of apoptosis in Parkinson's disease
25. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: Increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants
26. R-Deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium
27. Evidence of apoptotic cell death in HIV encephalitis
28. Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models
29. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety
30. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites
31. New insights into an old protein: The functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase
32. Evidence for apoptotic cell death in Alzheimer's disease
33. Immunohistochemical evidence for apoptosis in Alzheimer's disease
34. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
35. DNA end labelling (TUNEL) in Huntington's disease and other neuropathological conditions
36. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
37. Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus
38. Neurorescuing effects of the GAPDH ligand CGP 3466B
39. Apoptosis, retinitis pigmentosa, and degeneration
40. Apoptosis related antigen, Le(Y) and nick-end labelling are positive in spinal motor neurons in amyotrophic lateral sclerosis
41. Aliphatic propargylamines: Potent, selective, irreversible monoamine oxidase B inhibitors